PAP
DMAC icon

Persistent Asset Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Persistent Asset Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Buy
+2,613
New +$16.1K 0.01% 620

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Persistent Asset Partners's DMAC Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in DiaMedica Therapeutics (DMAC) in Q2 2026: 2,613 shares worth $18.4K. The stake represents 0.01% of the portfolio and ranks #620 among its holdings.

89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Persistent Asset Partners held 2,613 shares of DiaMedica Therapeutics worth $18.4K as of Q2 2026.
  • DiaMedica Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • DiaMedica Therapeutics made up 0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #620 holding.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.